Zhang_2022_Eur.J.Radiol_155_110507

OBJECTIVES: We aimed to evaluate [(68)Ga]Ga-DOTA-FAPI-04 versus [(18)F]FDG PET/CT in the application of fibroblastic tumors. METHODS: Twenty participants with 6 subtypes of fibroblastic tumors prospectively underwent (18)F-FDG and [(68)Ga]Ga-DOTA-FAPI-04 PET/CT examinations to evaluate the lesions. PET/CT findings were confirmed by surgical pathology of fifteen participants, puncture biopsy of two participants, or imaging follow-up of three participants. Two independent sample t tests were used to compare the uptake of [(18)F]FDG vs [(68)Ga]Ga-DOTA-FAPI-04 in primary, recurrent and metastatic lesions. One-way ANOVA was used to compare the uptake of [(18)F]FDG or [(68)Ga]Ga-DOTA-FAPI-04 among primary, recurrent, and metastatic lesions. The uptake of [(68)Ga]Ga-DOTA-FAPI-04 vs [(18)F]FDG in different histopathological lesions was compared by two independent sample t tests. RESULTS: Twenty participants were confirmed to have 38 lesions. Although there was no significant difference in the detection of lesions between [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG PET/CT (38 vs 36, p = 0.493), the uptake of [(68)Ga]Ga-DOTA-FAPI-04 in lesions was significantly higher than that of [(18)F]FDG (p < 0.001), including primary (p < 0.001), recurrent (p = 0.018) and metastatic (p < 0.001) lesions. The SUVmax of [(68)Ga]Ga-DOTA-FAPI-04 in primary and recurrent lesions was higher than that in metastasis (p = 0.034 and p = 0.015, respectively). The SUVmax of [(68)Ga]Ga-DOTA-FAPI-04 in primary and recurrent malignant lesions was significantly higher than that of the intermediate (p < 0.001). The SUVmax of [(68)Ga]Ga-DOTA-FAPI-04 in one participant of recurrent SFT with 5 lesions was significantly lower after treatment than before treatment (p = 0.016). CONCLUSIONS: [(68)Ga]Ga-DOTA-FAPI-04 outperformed [(18)F]FDG PET/CT in displaying the primary, recurrent and metastatic lesions of fibroblastic tumors.